| Income Statement | 2025-09-30 | 2025-03-31 | 2024-12-31 | |
|---|---|---|---|---|
| Total other (loss) income | -4,288,608 | -796,218 | 1,771,771 | |
| Income (loss) before income tax expense | -9,941,297 | 11,180,975 | -1,931,740 | |
| Income tax benefit | -34,793 | -81,186 | 11,609 | |
| Net loss | -9,906,504 | 11,262,161 | -1,943,349 | |
| Unrealized gain on foreign currency translation | 49,221 | -195,818 | -1,288,433 | |
| Total other comprehensive income | 49,221 | -195,818 | -1,288,433 | |
| Total comprehensive loss | -9,857,283 | 11,066,343 | -3,231,782 | |
| Earnings per share, basic, total | -4.41 | 6.55 | -1.23 | |
| Net income per share - diluted | -4.41 | 6.55 | -1.23 | |
| Weighted average shares - basic | 2,246,066 | 1,719,073 | 1,575,244 | |
| Weighted average shares - diluted | 2,246,066 | 1,719,073 | 1,575,244 | |
Neuphoria Therapeutics Inc. (NEUP)
Neuphoria Therapeutics Inc. (NEUP)